Freegriff,
I'm not sure why you keep telling me what you think is right and not right on the reasons why Amarantus (should not) own about 49% of TODOS.
You are going off of what you "think" or what your "gut is telling you", in either case it doesn't make it so.
It is reiterated time and time again in PR's and filings that Todos will complete it's transaction to purchase the rest of Breakthrough Diagnostics. The rest of the 80.01 % of Breakthrough will be in exchange for an additional 30.01% of Todos.
The independent third-party valuation came in and looks as if it was strong enough to support the deal.
Todos reiterated the deal will close after getting it.
Q3 looks to be the quarter this will all take place.
July 10, 2020
"We have started to ramp up sales, including a recent marquee sale of our ANDiS machines to the Cleveland Clinic, and we are now helping our clients get up and running so they can quickly expand their testing capacity."
"Todos expected to complete the remaining unowned interest in Breakthrough in the third quarter of 2020"
July 10, 2020
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the third quarter of 2020.
https://investor.todosmedical.com/news-events...-andis-350
April 17, 2020
Receives valuation of Alzheimer’s disease blood diagnostic LymPro Test
Retains Donohoe Advisors to assist with Nasdaq CM™ listing process
Todos Medical also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc. that is developing the proprietary immune-based Alzheimer’s disease blood diagnostic LymPro Test. Additionally, the Company announces that it has retained Donohoe Advisors to assist with its proposed listing on the Nasdaq CM™ national stock exchange in the United States.
Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd. (OTCQB: TOMDF) (19.99%). Breakthrough has been assigned the intellectual property and other rights to LymPro Test®, a diagnostic blood test for Alzheimer’s disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical owns an exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.
https://investor.todosmedical.com/news-events...s-board-of
April 9, 2020
Acquisition of Breakthrough Diagnostics, Inc. for Alzheimer’s blood diagnostic LymPro Test™
The Company has been seeking to complete the acquisition of Breakthrough Diagnostics due to the tremendous potential of the LymPro Test™ as a diagnostic blood test for Alzheimer’s disease. We have commissioned an independent third-party valuation of LymPro in order to fulfill the necessary requirements to complete the acquisition later this quarter.
https://investor.todosmedical.com/news-events...ate-update
Nov. 14, 2019
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd., has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ® from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise™ and Parkinson’s diagnostic NuroPro. Amarantus entered into a joint venture agreement with Todos Medical, Ltd. to advance diagnostic screening assets and Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 50% ownership of Todos.
https://investor.todosmedical.com/news-events...enrollment
May 28, 2019
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
Upon review of the LymPro data, Todos Medical exercised its exclusive option to acquire the remaining 80.01% of its joint venture Breakthrough Diagnostics from Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS). The transaction is expected to close upon listing of Todos’ common stock on a national stock exchange.
“Todos Medical was very pleased with the positive data we received from the University of Leipzig on the LymPro test,” said Herman Weiss, MD, President & CEO of Todos Medical
https://investor.todosmedical.com/news-events...ning-80-01
Feb., 28, 2019
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
"Todos Medical has closed the Joint Venture transaction with Amarantus Bioscience whereby Todos Medical issued to Amarantus 19.99% of the outstanding ordinary shares of Todos Medical, in exchange for 19.99% of Amarantus’s wholly-owned subsidiary Breakthrough Diagnostics, Inc. In addition, as part of the transaction, Amarantus has assigned to Breakthrough Diagnostics all of Amarantus’s rights to the LymPro Test®, an immune-based neurodiagnostic blood test for detection of Alzheimer’s disease, and other diagnostic assets. Breakthrough Diagnostics will focus on the development of the LymPro Test, which was originally developed at the University of Leipzig.
“We expect LymPro to help Todos Medical build upon its deep understanding of the interplay between immune system and aberrant cell proliferation processes that lead to disease. We believe this combination will help drive the clinical and commercial plan for LymPro and deliver significant shareholder value for Amarantus and Todos Medical.”
Under the terms of the JV Agreement, Todos Medical, has an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of Todos Medical’s shares. "
https://investor.todosmedical.com/news-events...-finalizes
Dec. 3, 2018. - 6K
"The exclusive option will be exercisable upon Amarantus entering into an
amended and restated license agreement with the University of Leipzig. The closing of the Joint Venture Transaction is subject to our raising $1,000,000 in equity or debt financing"
" As part of the Joint Venture Transaction, all rights to the LymPro Test and
certain other diagnostic assets will be assigned by Amarantus to Breakthrough Diagnostics"
Dec. 3, 2018
Under the terms of the JV Agreement, Todos Medical will issue to Amarantus 19.99% of the outstanding ordinary shares of Todos Medical stock, in exchange for 19.99% of a newly- formed entity called Breakthrough Diagnostics, Inc., with an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of Todos’ shares outstanding. All rights to LymPro and certain other diagnostic assets will be assigned to Breakthrough Diagnostics, as part of the transaction. Todos Medical's exclusive option will be exercisable upon Amarantus entering into an amended and restated license agreement with the University of Leipzig.
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
https://investor.todosmedical.com/news-events...ement-with
The Company also re-acquired rights to the Alzheimer’s blood diagnostic LymPro Test ®, MSPrecise™ and NuroPro.
I'm not sure why you keep telling me what you think is right and not right on the reasons why Amarantus (should not) own about 49% of TODOS.
You are going off of what you "think" or what your "gut is telling you", in either case it doesn't make it so.
It is reiterated time and time again in PR's and filings that Todos will complete it's transaction to purchase the rest of Breakthrough Diagnostics. The rest of the 80.01 % of Breakthrough will be in exchange for an additional 30.01% of Todos.
The independent third-party valuation came in and looks as if it was strong enough to support the deal.
Todos reiterated the deal will close after getting it.
Q3 looks to be the quarter this will all take place.
July 10, 2020
"We have started to ramp up sales, including a recent marquee sale of our ANDiS machines to the Cleveland Clinic, and we are now helping our clients get up and running so they can quickly expand their testing capacity."
"Todos expected to complete the remaining unowned interest in Breakthrough in the third quarter of 2020"
July 10, 2020
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the third quarter of 2020.
https://investor.todosmedical.com/news-events...-andis-350
April 17, 2020
Receives valuation of Alzheimer’s disease blood diagnostic LymPro Test
Retains Donohoe Advisors to assist with Nasdaq CM™ listing process
Todos Medical also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc. that is developing the proprietary immune-based Alzheimer’s disease blood diagnostic LymPro Test. Additionally, the Company announces that it has retained Donohoe Advisors to assist with its proposed listing on the Nasdaq CM™ national stock exchange in the United States.
Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd. (OTCQB: TOMDF) (19.99%). Breakthrough has been assigned the intellectual property and other rights to LymPro Test®, a diagnostic blood test for Alzheimer’s disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical owns an exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.
https://investor.todosmedical.com/news-events...s-board-of
April 9, 2020
Acquisition of Breakthrough Diagnostics, Inc. for Alzheimer’s blood diagnostic LymPro Test™
The Company has been seeking to complete the acquisition of Breakthrough Diagnostics due to the tremendous potential of the LymPro Test™ as a diagnostic blood test for Alzheimer’s disease. We have commissioned an independent third-party valuation of LymPro in order to fulfill the necessary requirements to complete the acquisition later this quarter.
https://investor.todosmedical.com/news-events...ate-update
Nov. 14, 2019
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd., has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ® from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise™ and Parkinson’s diagnostic NuroPro. Amarantus entered into a joint venture agreement with Todos Medical, Ltd. to advance diagnostic screening assets and Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 50% ownership of Todos.
https://investor.todosmedical.com/news-events...enrollment
May 28, 2019
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
Upon review of the LymPro data, Todos Medical exercised its exclusive option to acquire the remaining 80.01% of its joint venture Breakthrough Diagnostics from Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS). The transaction is expected to close upon listing of Todos’ common stock on a national stock exchange.
“Todos Medical was very pleased with the positive data we received from the University of Leipzig on the LymPro test,” said Herman Weiss, MD, President & CEO of Todos Medical
https://investor.todosmedical.com/news-events...ning-80-01
Feb., 28, 2019
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
"Todos Medical has closed the Joint Venture transaction with Amarantus Bioscience whereby Todos Medical issued to Amarantus 19.99% of the outstanding ordinary shares of Todos Medical, in exchange for 19.99% of Amarantus’s wholly-owned subsidiary Breakthrough Diagnostics, Inc. In addition, as part of the transaction, Amarantus has assigned to Breakthrough Diagnostics all of Amarantus’s rights to the LymPro Test®, an immune-based neurodiagnostic blood test for detection of Alzheimer’s disease, and other diagnostic assets. Breakthrough Diagnostics will focus on the development of the LymPro Test, which was originally developed at the University of Leipzig.
“We expect LymPro to help Todos Medical build upon its deep understanding of the interplay between immune system and aberrant cell proliferation processes that lead to disease. We believe this combination will help drive the clinical and commercial plan for LymPro and deliver significant shareholder value for Amarantus and Todos Medical.”
Under the terms of the JV Agreement, Todos Medical, has an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of Todos Medical’s shares. "
https://investor.todosmedical.com/news-events...-finalizes
Dec. 3, 2018. - 6K
"The exclusive option will be exercisable upon Amarantus entering into an
amended and restated license agreement with the University of Leipzig. The closing of the Joint Venture Transaction is subject to our raising $1,000,000 in equity or debt financing"
" As part of the Joint Venture Transaction, all rights to the LymPro Test and
certain other diagnostic assets will be assigned by Amarantus to Breakthrough Diagnostics"
Dec. 3, 2018
Under the terms of the JV Agreement, Todos Medical will issue to Amarantus 19.99% of the outstanding ordinary shares of Todos Medical stock, in exchange for 19.99% of a newly- formed entity called Breakthrough Diagnostics, Inc., with an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of Todos’ shares outstanding. All rights to LymPro and certain other diagnostic assets will be assigned to Breakthrough Diagnostics, as part of the transaction. Todos Medical's exclusive option will be exercisable upon Amarantus entering into an amended and restated license agreement with the University of Leipzig.
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
https://investor.todosmedical.com/news-events...ement-with
The Company also re-acquired rights to the Alzheimer’s blood diagnostic LymPro Test ®, MSPrecise™ and NuroPro.
2
